Sun Pharma initiates Phase II clinical trial on AQCH drug for treatment of COVID-19

05 Jun 2020 Evaluate
Sun Pharmaceutical Industries has commenced Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19. The company has received approval from the Drugs Controller General of India (DCGI) for conducting Phase II clinical trial in April this year.

The clinical trial will be conducted across 12 centers in India in 210 patients. The treatment duration for patients will be 10 days. The results of the clinical trial are expected by October 2020. Human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for Phase II study. The Drug has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with International Center for Genetic Engineering and Biotechnology (ICGEB), Italy

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1782.80 -14.45 (-0.80%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×